Glycosaminoglycanpolysulfate (GAGPS, Arteparon) for basic therapy of arthrosis. III. Biochemical-diagnostic and clinical studies on the intramuscular use of GAGPS
Bach, G.L.; Panse, P.; Zeiller, P.
Zeitschrift für Rheumatologie 36(7-8): 269-274
1977
ISSN/ISBN: 0340-1855 PMID: 919801 Document Number: 4182
Investigations using 3H-Arteparon (3H-glycosaminoglycan polysulfate, 3H-GAGPS) showed that in humans with degenerative joint disease an intramuscular administration of 125 mg GAGPS (0.5 ml Arteparon forte) produces GAGPS concentrations within the joint, which in a biochemical assay inhibit cartilage degrading lysosomal enzymes. The dosage was determined from animal experiments that had indicated the relationship between the applied quantity of the drug and the resulting biological concentrations. Preliminary results of treatment with 0.5 ml Arteparon forte in 15 patients are reported.
Document emailed within 1 workday
